Sanofi and the Vietnam Vaccine Company (VNVC) have officially launched a strategic collaboration focused on technology transfer for vaccine manufacturing. The initiative aims to enable the local production of select Sanofi vaccines in Vietnam, marking a new chapter in the country’s journey toward pharmaceutical self-reliance and public health resilience.

The partnership was commemorated during a high-level ceremony in Hanoi, graced by Vietnamese President Luong Cuong and French President Emmanuel Macron, symbolizing deepening bilateral cooperation in the healthcare and life sciences sectors.

Under the agreement, Sanofi will transfer vaccine production technology to VNVC and provide comprehensive support in workforce development and quality management practices. This includes technical training and process oversight to ensure adherence to international standards in vaccine research, manufacturing, and distribution.

“This collaboration reflects our long-standing commitment to improving access to vaccines globally and supports Vietnam’s ambition to become a regional vaccine hub,” said a Sanofi spokesperson. “By strengthening local capabilities, we aim to contribute to faster, more reliable responses to future health emergencies.”

As part of the initiative, VNVC also announced the construction of a state-of-the-art 26,000-square-meter vaccine manufacturing facility in Long An province. Backed by an initial investment of 2 trillion Vietnamese dong (approx. $77.2 million), the facility is projected to produce up to 100 million vaccine doses annually, significantly enhancing domestic supply security.

Launched in 2017, VNVC operates a national network of vaccination centers and has historically relied on imported vaccines from global pharmaceutical leaders. This latest partnership signals a shift toward homegrown production and aligns with Vietnam’s broader healthcare development goals.

The agreement is poised to establish a robust legal and operational framework for future collaboration between Vietnam and France in the areas of health, pharmaceuticals, and vaccine development. It builds on Sanofi’s recent global manufacturing investments, including major facilities in Canada, France, and Singapore, which collectively represent nearly $2 billion in infrastructure focused on vaccine innovation and accessibility.

Sanofi’s vaccine portfolio includes immunizations against influenza, meningitis, diphtheria, tetanus, pertussis, and other infectious diseases. The collaboration with VNVC reinforces the company’s commitment to global health equity and scalable, regional manufacturing solutions.